Exbivirumab/Libivirumab

N/A

Report date: 2025/05/20 15:00:28

Base Information

Drug NameExbivirumab/Libivirumab
Drug Alias NameMonoclonal antibody HBV-XTLHepatitis B MAb-XTLHuman anti-HBV-XTLHepeX-BXTL-001 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsHepatitis BRejection of liver transplantation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandGermany +[7] 
CombinationsYes
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesXtl Biopharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInotek Pharmaceuticals CorporationB&C PharmaCubist Pharmaceuticals Llc
Active IndicationsN/A
Inactive IndicationsHepatitis BRejection of liver transplantation

Other Information

ATC CodeN/A
Related LinksN/A